Innodata Inc.

Investors should pay attention to the securities of mid-cap company Innodata, which helps big tech players train their AI models, <a href="https://www.fool.com/investing/2025/11/03/1-tech-stock-to-buy-before-the-end-of-2025/">says</a> The Motley Fool. Thanks to increased demand for these services, Innodata's stock has <a href="https://finance.yahoo.com/quote/INOD/">jumped</a> nearly 83% since the beginning of the year and that's just the beginning, the article says.

Google's Mid-cap partner grew 83% in 2025. Why the Motley Fool advises buying

Sarepta Therapeutics, Inc.

Shares of Sarepta Therapeutics, a mid-cap developer of therapies for rare diseases, <a href="https://finance.yahoo.com/quote/SRPT/">plummeted</a> nearly 40% in the postmarket on Nov. 3. Investors were reacting to the company's <a href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial">news</a> that it had failed extended trials for <a href="https://www.sarepta.com/products-pipeline/products">two of</a> its <a href="https://www.sarepta.com/products-pipeline/products">key</a> developments. They are already on sale in the US, but the new data <a href="https://www.bloomberg.com/news/articles/2025-11-03/sarepta-says-older-duchenne-drugs-failed-confirmatory-trial">could lead</a> to a recall of the drugs from the market.

Shares in biotech Sarepta collapsed 40% overnight. It failed a clinical trial

Beta Technologies

The company raised over $1 billion in its initial public offering

IPO of electric airplane maker Beta: "Tesla in the Sky" shares become available

Enphase Energy, Inc.

Freedom Broker lowered by 22% its target price for Enphase Energy, a mid-cap developer of solar energy solutions. While the company’s third-quarter <a href="https://investor.enphase.com/static-files/6f4421c0-8777-4bc0-8a55-f4f7c3685f07">results</a>&nbsp;significantly beat market expectations, it surprised investors to the downside with its outlook for 2026, which points to a sharp decline in demand.

Freedom cuts target price of energy tech Enphase on dim 2026 guidance

Davide Campari-Milano N.V.

Shares of Davide Campari-Milano N.V., the maker of Campari, Aperol, and Cinzano, <a href="https://finance.yahoo.com/quote/CPR.MI/">fell</a>&nbsp;6% in&nbsp;trading in Milan early today, November 3, after Italian prosecutors <a href="https://www.gdf.gov.it/it/gdf-comunica/notizie-ed-eventi/comunicati-stampa/anno-2025/novembre/sequestro-preventivo-per-un-valore-di-oltre-un-miliardo-di-euro">seized</a>&nbsp;about EUR1.3 billion worth of its stock held by controlling shareholder Lagfin SCA as part of a tax-fraud investigation.

Aperol maker suffers worst drop since April amid Italian tax probe

The Beachbody Company, Inc.

Investors should consider buying shares of micro-cap fitness and nutrition company the <a href="https://thebeachbodycompany.com/overview/default.aspx">Beachbody Company</a>, which has upside of almost 150%, Noble Capital Markets <a href="https://dashboard.channelchek.com/wp-content/uploads/pdf/BODI_20251028_27773.pdf">said</a>&nbsp;in an initiation report. After several years of declining revenue, analysts believe the company is on the cusp of recovery, helped in part by the "current GLP-1 phenomenon."

Noble initiates on Beachbody Company with 'buy' as beneficiary of 'GLP-1 phenomenon'

Crocs, Inc.

Footwear manufacturer Crocs reported the first decline in sales of its namesake brand in five years. Third-quarter revenue for the Crocs brand fell 2.5% year over year to $836 million, the company <a href="https://investors.crocs.com/news-and-events/press-releases/press-release-details/2025/Crocs-Inc--Reports-Third-Quarter-2025-Results/default.aspx">said</a>&nbsp;in the earnings release yesterday, October 30. It is the first drop since the second quarter of 2020, MarketWatch <a href="https://www.marketwatch.com/story/has-crocs-demand-peaked-sales-just-dropped-and-are-expected-to-keep-falling-8d5a5e37?mod=newsviewer_click_seemore">notes</a>. In the current quarter, the company also expects Crocs-brand sales to decline about 3%.

Crocs sales decline for first time since 2020 and are expected to keep falling

Absci Corporation

Applied Digital Corporation

Relay Therapeutics, Inc.

For small-cap stocks, late summer was a turning point. At Jackson Hole, Fed Chair Jerome Powell signaled that the tight monetary policy was nearing an end. For small caps, whose profitability is especially sensitive to borrowing costs, that implied a reset in expectations. Tech added fuel: a pickup in new contracts to build AI data centers and strong demand for products from leaders such as Nvidia, Oracle, and TSMC reinforced the idea that even smaller tech names can ride the ongoing AI boom.

A rising tide lifts all boats: How tech small caps gained from the AI boom in 3Q25

Krispy Kreme, Inc.

Opendoor Technologies Inc.

Beyond Meat, Inc.

Cracker Barrel Old Country Store, Inc.

In October, short sellers ramped up pressure on small- and mid-cap stocks, <i>Barron’s </i><a href="https://www.barrons.com/articles/short-sellers-small-caps-meme-stocks-06a426a1?st=5FGUar">reports</a>. Short interest in these companies rose to 7.5% from 7.3% in September, according to Melissa Roberts, an analyst with Stephens. For megacaps, it edged down to 1.8% from 1.9%. Roberts flagged healthcare small caps and mid-cap consumer-lending names among the most targeted stocks.

Shorts are coming after small- and mid-cap stocks. Which names are feeling pressure?

Victoria's Secret & Co.

UBS has <a href="https://seekingalpha.com/news/4510219-victorias-secret-rallies-after-ubs-pitches-the-bull-case">upgraded</a>&nbsp;Victoria’s Secret, one of the world’s best-known lingerie retailers, to “buy,” saying the management is capable of restoring sustainable growth after several years of declining sales. The bank’s target price offers 27% upside.

UBS upgrades Victoria’s Secret to 'buy' on growing conviction in management

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

eToro Group Ltd.

Klarna

Navan, Inc. Class A Common Stock

The company raised $923.1 million and will list on the Nasdaq

Israeli business-travel firm Navan goes public in U.S., trading opens

Douglas Dynamics, Inc.

Freedom Broker recommends clients buy shares of Douglas Dynamics, a small manufacturer of snow-clearing equipment whose stock is up more than 30% year to date. The target price set for Douglas securities is 20% above current quotes. Sustainable growth is supported by well-known brands, a wide dealer network, and a balanced sales structure, analysts say.

Freedom initiates on snowplow maker Douglas with 'buy,' TP implying 20% upside

Zedge, Inc.

Shares of Zedge, a micro-cap company that created an emoji encyclopedia and sells ringtones and wallpapers for cell phones, plummeted more than 24% yesterday, October 28. Investors reacted to the company’s fourth-quarter and fiscal-full-year <a href="https://feeds.issuerdirect.com/news-release.html?newsid=7206297427461208&amp;symbol=ZDGE">earnings</a>, with declines across all key financial indicators. The selloff was not tempered by promises about 2026 as "a year of innovation focused on unlocking growth."

Emoji encyclopedia owner Zedge plunges 24% on disappointing fiscal-2025 results

Serve Robotics Inc.

Symbotic Inc.

NIO Inc.

Motley Fool analyst Leo Sun has <a href="https://www.fool.com/investing/2025/10/28/growth-stocks-that-could-be-10-baggers-in-10-years/">highlighted</a>&nbsp;three undervalued stocks that, in his view, could deliver tenfold returns over the next decade. One of them is small-cap company Serve Robotics, a developer of autonomous delivery robots. The other two are warehouse-automation firm Symbotic and Chinese EV maker Nio.

Motley Fool names three growth stocks with 10x upside over a decade

Spotify Technology S.A.

Shares of Swedish audio streaming giant Spotify fell in price by more than 5% at the opening of trading on November 4, then recovered the fall and again went down by 2.5%. This is how the market reacted to the publication of the company's financial <a href="https://newsroom.spotify.com/2025-11-04/spotify-q3-2025-earnings">report</a> for the third quarter. It managed to exceed Wall Street's expectations in terms of revenue, margin and user growth. But advertising revenues declined, and the forecast for the current quarter did not encourage investors.

Spotify has increased revenue and audience, but the stock is down. Is it worth buying them?

Uber Technologies, Inc.

Shares of cab ordering service Uber fell nearly 7% despite a strong third-quarter earnings <a href="https://investor.uber.com/news-events/news/press-release-details/2025/Uber-Announces-Results-for-Third-Quarter-2025/default.aspx">report</a>. Investors were likely disappointed that operating profit after deducting one-time tax and investment incentives fell short of estimates. Still, 80% of analysts on Wall Street advise buying Uber stock, which is up 65% YTD.

Uber reported revenue growth. Why did its stock fall?

Palantir Technologies Inc.

NVIDIA Corporation

Palantir CEO and founder Alex Karp had harsh words for shortsellers, particularly Michael Burry, after the famed investor from the movie "The Down Game" bet against Palantir and Nvidia stock in the latest quarter results.

'Just crazy': Palantir chief responds to investor shorting from 'downgrade game' 

lululemon athletica inc.

Michael Burry purchased options that would make him a profit if the stock of these companies fell

Investor in the "Downgrade Game" bet against Nvidia and Palantir

Markets could experience a correction of more than 10% over a period of 12 to 24 months, Goldman Sachs and Morgan Stanley executives warned at a summit in Hong Kong, CNBC <a href="https://www.cnbc.com/2025/11/04/goldman-sachs-morgan-stanley-warn-of-a-market-correction.html">writes </a>. After the 2025 rally, which is being fueled by the AI boom and Fed policy easing and not stopped by a government shutdown, it will be a "reality check," the channel said.

The heads of Goldman and Morgan Stanley allowed a correction of at least 10%. They are not concerned

Latest Small Caps Stock News and Analysis